You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis - An open clinical trial-
|
|---|---|
| Published in |
BMC Clinical Pharmacology, March 2010
|
| DOI | 10.1186/1472-6904-10-7 |
| Pubmed ID | |
| Authors |
Kenji Kumagai, Susumu Shirabe, Noriaki Miyata, Masakazu Murata, Atsushi Yamauchi, Yasuhumi Kataoka, Masami Niwa |
| Abstract |
Pentosan polysulfate sodium (pentosan) is a semi-synthetic drug manufactured from beech-wood hemicellulose by sulfate esterification of the xylopyranose hydroxyl groups. From in vitro and animal model studies, pentosan has been proposed as a disease modifying osteoarthritis drug (DMOAD). The objective of this study was to assess the efficacy, safety, and patient satisfaction in patients with mild radiographic knee osteoarthritis (OA) findings and OA-associated symptoms and signs. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Serbia | 1 | 50% |
| United Kingdom | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Norway | 1 | 1% |
| Unknown | 71 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 19% |
| Other | 7 | 10% |
| Student > Bachelor | 6 | 8% |
| Student > Doctoral Student | 5 | 7% |
| Student > Master | 5 | 7% |
| Other | 13 | 18% |
| Unknown | 22 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 29% |
| Agricultural and Biological Sciences | 4 | 6% |
| Veterinary Science and Veterinary Medicine | 4 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Nursing and Health Professions | 2 | 3% |
| Other | 11 | 15% |
| Unknown | 27 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2022.
All research outputs
#2,920,462
of 24,068,839 outputs
Outputs from BMC Clinical Pharmacology
#12
of 58 outputs
Outputs of similar age
#11,363
of 98,196 outputs
Outputs of similar age from BMC Clinical Pharmacology
#2
of 2 outputs
Altmetric has tracked 24,068,839 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 58 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 98,196 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.